---
title: "Regeneron Says FDA Approves Pasatru (Garetosmab-Grts) For Adults With Fibrodysplasia Ossificans Progressiva"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296391680.md"
datetime: "2026-08-19T19:19:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296391680.md)
  - [en](https://longbridge.com/en/news/296391680.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296391680.md)
generator: "portal-rs"
---

# Regeneron Says FDA Approves Pasatru (Garetosmab-Grts) For Adults With Fibrodysplasia Ossificans Progressiva

Aug 20 (Reuters) - Regeneron Pharmaceuticals, Inc. (REGN.O) : \* REGENERON PHARMACEUTICALS, - FDA APPROVES PASATRU (GARETOSMAB-GRTS) FOR ADULTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA \* REGENERON PHARMACEUTICALS, - PASATRU UNDER REVIEW BY EUROPEAN MEDICINES AGENCY; GLOBAL SUBMISSIONS PLANNED Source text: Further company coverage: (REGN.O)

### Related Stocks

- [REGN.US](https://longbridge.com/en/quote/REGN.US.md)

## Related News & Research

- [Regeneron says FDA approves Pasatru for adults with rare bone disorder FOP](https://longbridge.com/en/news/296387064.md)
- [B. Metzler seel. Sohn & Co. AG Grows Stock Position in Regeneron Pharmaceuticals, Inc. $REGN](https://longbridge.com/en/news/298098855.md)
- [Pasithea Therapeutics to present initial Phase 1/1b PAS-004 data in adult NF1 trial at 2026 European Neurofibromatosis Conference](https://longbridge.com/en/news/298907204.md)
- [Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears](https://longbridge.com/en/news/298780449.md)
- [Grasim Reports Customs Search at Fibre Unit, Says No Material Impact](https://longbridge.com/en/news/298808880.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**